AMH Equity’s Myriad Genetics MYGN Stock Holding History

AMH Equity’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$2.89M	Buy	400,000 +100,000	+33%	+$594K	3.6%	7
2025 Q2	$1.59M	Buy	+300,000	New	+$1.77M	2.09%	19
2024 Q2	–	Sell	-110,000	Closed	-$2.35M	–	39
2024 Q1	$2.35M	Buy	+110,000	New	+$2.36M	2.3%	15
2023 Q4	–	Sell	-47,285	Closed	-$758K	–	41
2023 Q3	$758K	Sell	47,285 -62,715	-57%	-$1.19M	0.83%	22
2023 Q2	$2.55M	Buy	+110,000	New	+$2.4M	2.91%	11

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AMH Equity's MYGN Position: Q3 2025 in Review

AMH Equity increased its Myriad Genetics (MYGN) stake by 33% in Q3 2025, buying an estimated $594K and bringing the position to 400,000 shares worth $2.89M. The position accounts for 3.6% of the portfolio, ranked #7.

AMH Equity first reported a position in MYGN in Q2 2023 and has held it in 5 quarters since. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

AMH Equity held 400,000 shares of Myriad Genetics worth $2.89M as of Q3 2025.
AMH Equity bought 100,000 Myriad Genetics shares in Q3 2025, an estimated $594K.
Myriad Genetics made up 3.6% of AMH Equity's portfolio in Q3 2025, its #7 holding.
AMH Equity first reported a position in Myriad Genetics in Q2 2023 and has held it in 5 quarters since.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on AMH Equity's 13F filing for Q3 2025, filed 29 Oct 2025.